Quality of Life and Economic Repercussions of Combining Proactive Medication Assessment and Electronic Monitoring of Toxicities in Subjects Undergoing Oral Cancer Therapy

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · Apr 25, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring how a new approach to monitoring patients receiving oral cancer treatments can improve their quality of life and potentially reduce healthcare costs. The study involves regular consultations with a hospital pharmacist who will proactively assess medications and identify any possible drug interactions. Patients will also provide feedback on their side effects and overall well-being using an electronic system. This method aims to catch issues early, allowing for better management of side effects, which can be missed during regular doctor visits.

To join the trial, participants should be starting treatment for advanced cancer with oral medications, have access to a smartphone, tablet, or computer, and be able to use the internet. They will also need to be in generally good health and have health insurance. Throughout the study, participants can expect close monitoring and support to help improve their treatment experience and health outcomes. This trial is currently recruiting patients and aims to understand both the health benefits and the economic implications of this new care approach.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient starting oral therapy treatment in oncology for metastatic or locally advanced cancer
• • Patient able to use a connected electronic object
• • Patient with a smartphone/tablet or computer with internet access and an email address.
• • Patient with WHO status ≤2
• • Patients receiving other cancer therapy concurrently with oral therapy may be included
• • The patient must have given their free and informed consent and signed the consent form
• • The patient must be a member or beneficiary of a health insurance plan
• Exclusion Criteria:
• • The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
• • The subject refuses to sign the consent
• • It is impossible to give the subject informed information
• • The patient is under safeguard of justice or state guardianship
• • Patient pregnant, parturient or breast feeding
• • Illiterate patient
• • Patients with poor prognosis due to a serious uncontrolled medical condition, mild systemic disease, uncontrolled infection (cardiac, pulmonary, renal, etc.)
• • Patient receiving hormone therapy alone for breast or prostate cancer